Floatz logo

Daunomycin

Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent cohort.

Asset / SponsorPhaseRating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
Azacitidine
National Cancer Institute (NCI)
Phase 2BB
CYTARABINE
National Cancer Institute (NCI)
Phase 2BB
CASPOFUNGIN
Children's Oncology Group
Phase 3BB
Fluconazole
Children's Oncology Group
Phase 3BB

View all 20 →

Same molecule, other indications

Daunomycin is also rated in:

acute myeloid leukemia by FAB classificationActive
BBB
Indicative · Phase 3
78 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesActive
BBB
Indicative · Phase 3
77 / 100
View asset →
acute monocytic leukemiaActive
BBB
Indicative · Phase 3
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →